From the Court to Commerce: Tennis Champion Rafael Nadal to Headline VTEX Connect Europe 2025

14.10.2025 17:08:00 CEST | Business Wire | Press Release

VTEX (NYSE: VTEX), the sole Customers’ Choice commerce platform for two years by Gartner® and trusted by global brands including Colgate, Stanley Black & Decker, and Whirlpool, announces that 22-time Grand Slam tennis champion and entrepreneur Rafael Nadal, will headline VTEX Connect Europe on November 11, 2025, at Pavilhão Carlos Lopes in Lisbon, Portugal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014941918/en/

Held alongside Web Summit 2025, the world’s largest technology gathering, VTEX Connect Europe on November 11 has become the premier evening for global digital commerce to unite. The event will bring together thousands from retail, manufacturing, and technology to uncover ways enterprise digital commerce and AI has transformed operations, customer experience, and growth strategy. This year’s event will also feature an in-depth conversation with Rafael Nadal, including how he is approaching his entrepreneurial ventures in an AI-driven world.

“Performance in sport comes from mastery and precision. At VTEX, we see that same clarity in how enterprises deploy AI to orchestrate multi-channel commerce operations with control, speed, and measurable results,” said Santiago Naranjo, Chief Revenue Officer at VTEX. “We’re bringing that same energy and innovation to VTEX Connect Europe this year, complementing Web Summit 2025 week in Lisbon, with exciting surprises and insights that will shape the future of enterprise commerce.”

Additional Highlights at VTEX Connect Europe, November 11:

RedCloud to unveil its AI-native vision for transforming global trade operations.
Manchester City FC and more special guests from top global brands and technology partners will highlight innovations shaping the next era of enterprise commerce.

View the full agenda and register:vtexconnect.vtex.com/live-lisbon

Event Details:

Date: November 11, 2025
Venue: Pavilhão Carlos Lopes, Lisbon, Portugal
Time: 17:00–23:00 CEST
Media inquiries:newsroom@vtex.com

ABOUT US: VTEX (NYSE: VTEX) is the backbone of AI-connected commerce, built for enterprises that adapt with precision and demand results in retail (B2C) and industrial manufacturing and distribution (B2B). VTEX’s unified commerce platform delivers omnichannel sales, intelligent order management, data pipelines, retail media, enterprise-grade security, and more. Each capability is designed to remove friction, connect global commerce operations, and accelerate growth. VTEX offers both composable and out-of-the-box solutions, powering over 2,400 brands, including Colgate, Sony, Stanley Black & Decker, and Whirlpool. Today, VTEX powers more than 3,400 active storefronts across 43 countries (fiscal year ended December 31, 2024). Learn more at vtex.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014941918/en/

Contacts

Kate Adams
PAN Communications
VTEX@pancomm.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom